sirnaomicsltd
HONG KONG, Dec 30, 2021 - (ACN Newswire) - Sirnaomics Ltd. ("Sirnaomics" or "Company", together with its subsidiaries, the "Group", stock code: 2257.HK), the RNA therapeutics biopharmaceutical company with strong presence in both China and the U.S., and the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutics, is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today. The total number of offer shares under the Global Offering amounts to 7,540,000 shares, with the final offer price determi...
ACN Newswire
Offer price between HK$65.90 and HK$72.70 per share HONG KONG, Dec 19, 2021 - (ACN Newswire) - Sirnaomics Ltd. ("Sirnaomics" or "Company", stock code: 2257.HK), the RNA therapeutics biopharmaceutical company withs strong presence in both China and the U.S., today announces the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK"). Sirnaomics plans to offer an aggregate of 7,540,000 Offer Shares under the Global Offering (subject to the Over-allotment Option), consisting of 6,786,000 International Offer Shares (subject to reallocation and the Over-...
ACN Newswire
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら